No results for ‘’
Lyka Labs Ltd
₹67.38
(3.83%)
Tue, 23 Jun 2026, 03:00 am
Health Technology
Pharmaceuticals: Other
24.5KLyka Labs Ratios
| Particulars | 2005 | 2006 | 2007 | 2009 | 2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 15.43 | 0 | 29.30 | 0 | 0 | 0 | 47.67 | 0 | 0 | 0 | 0 | 0 | 9.98 | 0 | 0 | 44.83 |
| Price to book ratio | 2.16 | 1.11 | 1.03 | 0.84 | 0.67 | 0.33 | 0.30 | 0.77 | 4.05 | 3.19 | 2.61 | 1.60 | 0 | 0 | 29.17 | 7.07 | 5.14 | 3.48 |
| Price to sales ratio | 1.24 | 0.58 | 0.72 | 0.49 | 0.49 | 0.22 | 0.16 | 0.44 | 1.35 | 1.12 | 2.02 | 1.02 | 0.60 | 0.88 | 2.02 | 3.29 | 3.18 | 2.61 |
| Price to cash flow ratio | 2.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0.58 | 0 | 8.99 | 67.68 | 3.51 | 0 | 24.60 | 6.75 | 0 | 0 | 0 |
| Enterprise value | 116Cr | 83.58Cr | 117Cr | 154Cr | 180Cr | 151Cr | 169Cr | 190Cr | 283Cr | 248Cr | 232Cr | 166Cr | 168Cr | 231Cr | 503Cr | 365Cr | 402Cr | 397Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 15.83 | 18.82 | 9.66 | 23.89 | 12.76 | 135.51 | 16.03 | 12.13 | 0 | 0 | 0 | 12.74 | 5.23 | 23.16 | 28.14 | 23.46 |
| Debt to equity ratio | 2.23 | 1.27 | 0.70 | 1.27 | 1.12 | 1.74 | 2.30 | 3.08 | 2.57 | 3.33 | 2.28 | 2.24 | 0 | 0 | 9.78 | 1.65 | 0.86 | 0.38 |
| Return on equity % | 0 | -30.25 | 6.75 | 0 | 2.61 | -0.55 | -1.02 | 0 | 7.75 | -13.87 | -39.63 | -12 | -423.07 | 0 | 0 | -44.95 | -4.38 | 9.33 |
Lyka Labs Ltd Ratios
The Lyka Labs Ltd Ratios page provides a complete fundamental analysis of Lyka Labs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Lyka Labs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Lyka Labs Ltd (NSE: LYKALABS, BSE: 500259) is currently trading at ₹67.38, with a market capitalization of ₹242.37Cr. As a major player in the Health technology sector and Pharmaceuticals: other industry, Lyka Labs Ltd remains a key stock for fundamental analysis using Lyka Labs Ltd Ratios.
Lyka Labs Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Lyka Labs Ltd P/E ratio currently stands at 44.83, making it one of the most tracked metrics in Lyka Labs Ltd Ratios.
Historically, the Lyka Labs Ltd P/E ratio has shown strong fluctuations:
- 2024: 44.83
- 2023: 0
- 2022: 0
- 2021: 9.98
- 2020: 0
The rising Lyka Labs Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Lyka Labs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.48.
Historical P/B trend:
- 2024: 3.48
- 2023: 5.14
- 2022: 7.07
- 2021: 29.17
Lyka Labs Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Lyka Labs Ltd P/S ratio currently stands at 2.61, an important part of Lyka Labs Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 2.61
- 2023: 3.18
- 2022: 3.29
- 2021: 2.02
A stable or declining Lyka Labs Ltd P/S ratio indicates cautious market sentiment.
Lyka Labs Ltd Price to Cash Flow Ratio (P/CF)
The Lyka Labs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.
Historical Lyka Labs Ltd Price to Cash Flow Ratio:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 6.75
- 2020: 24.60
The declining Lyka Labs Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Lyka Labs Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Lyka Labs Ltd EV currently stands at ₹397Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 397Cr
- 2023: 402Cr
- 2022: 365Cr
- 2021: 503Cr
Lyka Labs Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Lyka Labs Ltd EV/EBITDA ratio is currently 23.46, a key metric in Lyka Labs Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 23.46
- 2023: 28.14
- 2022: 23.16
- 2021: 5.23
Stable Lyka Labs Ltd EV/EBITDA indicates balanced valuation.
Lyka Labs Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Lyka Labs Ltd D/E ratio is currently 0.38, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.38
- 2023: 0.86
- 2022: 1.65
- 2021: 9.78
Lyka Labs Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Lyka Labs Ltd ROE currently stands at 9.33%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 9.33
- 2023: -4.38
- 2022: -44.95
- 2021: 0
Declining ROE indicates pressure on profitability.
Lyka Labs Ltd Ratios Analysis Summary
The Lyka Labs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Lyka Labs Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Lyka Labs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.